Screening, diagnosis, and treatment of dyslipidemia among persons with persistent mental illness: A literature review

Psychiatric Services

Volumn 63, Issue 7, 2012, Pages 693-701

  Vanderlip, Erik R ^a   Fiedorowicz, Jess G ^a,b   Haynes, William G ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONSTIPATION; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DYSLIPIDEMIA; DYSPEPSIA; FATIGUE; GALLSTONE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTRANSAMINASEMIA; HYPERURICEMIA; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIVER TOXICITY; MENTAL DISEASE; METABOLIC SYNDROME X; MYALGIA; MYOPATHY; REVIEW; RISK REDUCTION; SCREENING; SINUSITIS; SMOKING CESSATION; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; MASS SCREENING; MENTAL DISORDERS;

EID: 84863601366     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201100475     Document Type: Review

References (81)

1. Ford ES, Mokdad AH, Giles WH, et al: Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 107:2185-2189, 2003 (Pubitemid 36547210)
2. LaRosa J, Hunninghake D, Bush D, et al: The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation 81:1721-1733, 1990
3. Kannel WB, Castelli WP, Gordon T, et al: Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Annals of Internal Medicine 74:1-12, 1971
4. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
5. Fiedorowicz JG, He J, Merikangas KR: The association between mood and anxiety disorders with vascular diseases and risk factors in a nationally representative sample. Journal of Psychosomatic Research 70:145-154, 2011
6. Colton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 3(2):A42; Epub March 15, 2006
7. Miller BJ, Paschall CB, Svendsen DP: Mortality and medical comorbidity among patients with serious mental illness. Psychiatric Service 57:1482-1487, 2006 (Pubitemid 44671660)
8. Parks J, Pollack D, Bartels S, et al: Integrating Behavioral Health and Primary Care Services? Opportunities and Challenges for State Mental Health Authorities. Technical Report. Alexandria, Va, National Association of State Mental Health Program Directors, Medical Directors Council, 2005
9. Osby U, Correia N, Brandt L, et al: Time trends in schizophrenia mortality in Stockholm County, Sweden. BMJ 321:483-484, 2000 (Pubitemid 30623604)
10. Saha S, Chant D, McGrath J: A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry 64:1123-1131, 2007 (Pubitemid 47529346)
11. McDonald M, Hertz RP, Lustik MB, et al: Healthcare spending among community-dwelling adults with schizophrenia. American Journal of Managed Care 11(suppl 8):S242-S247, 2005 (Pubitemid 41361625)
12. De Hert M, van Winkel R, Van Eyck D, et al: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research 83:87-93, 2006
13. Nasrallah H, Meyer JM, Goff DC, et al: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86:15-22, 2006 (Pubitemid 44234064)
14. Saari K, Lindeman SM, Viilo KM: A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. Journal of Clinical Psychiatry 66:559-563, 2005 (Pubitemid 40733696)
15. Brown S, Birtwistle J, Roe L, et al: The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 29:697-701, 1999 (Pubitemid 29261358)
16. Compton MT, Daumit GL, Druss BG: Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harvard Review of Psychiatry 14:212-222, 2006 (Pubitemid 44260109)
17. Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research 70:1-17, 2004 (Pubitemid 38916622)
18. Meltzer H, Bonaccorso S, Bobo W, et al: A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. Journal of Clinical Psychiatry 72:1602-1610, 2011
19. Aliyazicioglu R, Kural B, Colak M, et al: Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder. Tohoku Journal of Experimental Medicine 213:79-87, 2007 (Pubitemid 47516904)
20. Morrato EH, Nicol GE, Maahs D, et al: Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics and Adolescent Medicine 164: 344-351, 2010
21. Newcomer JW: Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. Journal of Clinical Psychiatry 68(suppl 1):20-27, 2007
22. Newcomer JW, Campos JA, Marcus RN, et al: A multicenter, randomized, doubleblind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. Journal of Clinical Psychiatry 69:1046-1056, 2008 (Pubitemid 352031586)
23. Newcomer JW, Nasrallah H, Loebel AD: The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. Journal of Clinical Psychopharmacology 24(5 suppl 1):S1-S6, 2004 (Pubitemid 39265948)
24. Druss BG, Rosenheck R, Desai MM, et al: Quality of preventive medical care for patients with mental disorders. Medical Care 40:129-136, 2002
25. Morden NE, Mistler L, Weeks WB, et al: Health care for patients with serious mental illness: family medicine's role. Journal of the American Board of Family Medicine 22:187-195, 2009
26. Horvitz-Lennon M, Kilbourne AM, Pincus HA: From silos to bridges: meeting the general health care needs of adults with severe mental illnesses. Health Affairs 25:659-669, 2006 (Pubitemid 43824915)
27. Alakeson V, Frank RG, Katz RE: Specialty care medical homes for people with severe, persistent mental disorders. Health Affairs 29:867-873, 2010
28. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18:499-502, 1972
29. Contois JH, Warnick GR, Sniderman AD: Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. Journal of Clinical Lipidology 5:264-272, 2011
30. Baigent C, Keech, Kearney PM, et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278, 2005
31. Screening for Lipid Disorders in Adults. Rockville, Md, US Preventive Services Task Force, 2008. Available at www.uspreventiveservicestaskforce.org/ uspstf/uspschol.htm
32. Kreinin A, Novitski D, Rabinowitz D, et al: Association between tobacco smoking and bipolar affective disorder: clinical, epidemiological, cross-sectional, retrospective study in outpatients. Comprehensive Psychiatry, PMID: 21664608; Epub June 9, 2011
33. Correll CU, Druss BG, Lombardo I, et al: Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatric Services 61: 892-898, 2010
34. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, et al: Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Annals of Clinical Psychiatry; 20:131-137, 2008 (Pubitemid 352009283)
35. Allison DB, Fontaine KR, Heo M, et al: The distribution of body mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry 60:215-220, 1999 (Pubitemid 29193917)
36. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27:596-601, 2004
37. Sernyak MJ: Implementation of monitoring and management guidelines for second-generation antipsychotics. Journal of Clinical Psychiatry 68(suppl 4):14-18, 2007
38. Marder S, Essock S, Miller A, et al: Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161:1334-1349, 2004 (Pubitemid 38989085)
39. Diagnosis and classification of diabetes mellitus. Diabetes Care 33(suppl 1):S62-S69, 2010
40. Di Angelantonio E, Sarwar N, Perry P, et al: Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993-2000, 2009
41. Mora S, Rifai N, Buring JE, et al: Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 118: 993-1001, 2008
42. Grundy SM, Cleeman JI, Merz CNB, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004 (Pubitemid 38924592)
43. Genest J, McPherson R, Frohlich J, et al: 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations. Canadian Journal of Cardiology 25:567-579, 2009
44. Hooper L, Summerbell C, Higgins J, et al: Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database of Systematic Reviews 3:CD 002137, 2001
45. Katcher HI, Hill AM, Lanford JLG, et al: Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise LDL-cholesterol. Endocrinology and Metabolism Clinics of North America; 38:45-78, 2009
46. Van Horn L, McCoin M, Kris-Etherton PM, et al: The evidence for dietary prevention and treatment of cardiovascular disease. Journal of the American Dietetic Association 108:287-331, 2008
47. Parmley WW: In the statin era, how important are intense lifestyle changes? Journal of the American College of Cardiology 41:273-274, 2003
48. Liu J, Zhang J, Shi Y, et al: Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese Medicine 1:4, 2006; doi: 10.1186/1749-8546-1-4
49. von Schacky C, Harris WS: Cardiovascular benefits of omega-3 fatty acids. Cardiovascular Research 73:310-315, 2007
50. Heart Prevention Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:23-33, 2002
51. De Hert M, Dekker JM, Wood D, et al: Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology. European Psychiatry 24:412-424, 2009
52. Daumit GL, Goldberg RW, Anthony C, et al: Physical activity patterns in adults with severe mental illness. Journal of Nervous and Mental Disease 193:641-646, 2005 (Pubitemid 41475857)
53. Van Citters AD, Pratt SI, Jue K, et al: A pilot evaluation of the In SHAPE individualized health promotion intervention for adults with mental illness. Community Mental Health Journal 46:540-552, 2010
54. Cabassa LJ, Ezell JM, Lewis-Fernández R: Lifestyle interventions for adults with serious mental illness: a systematic literature review. Psychiatric Services 61:774-782, 2010
55. Alvarez-Jiménez M, Hetrick SE, González-Blanch C, et al: Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. British Journal of Psychiatry 193:101-107, 2008
56. Kelly RB: Diet and exercise in the management of hyperlipidemia. American Family Physician 81:1097-1102, 2010
57. Jenkins DJA, Kendall CWC, Marchie A: Diet and cholesterol reduction. Annals of Internal Medicine 142:793-795, 2005 (Pubitemid 40593782)
58. Jenkins DJA, Jones PJH, Lamarche B, et al: Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia. JAMA 306:831-839, 2011
59. Lindholm LH, Mendis S: Prevention of cardiovascular disease in developing countries. Lancet 370:720-722, 2007 (Pubitemid 47320784)
60. Weiden PJ: Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. Journal of Clinical Psychiatry 68(suppl 4):34-39, 2007
61. Stroup TS, McEvoy JP, Ring KD, et al: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems. American Journal of Psychiatry 168:947-956, 2011
62. Borba CPC, Fan X, Copeland PM, et al: Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. Journal of Clinical Psychopharmacology 31:653-658, 2011
63. Narula PK, Rehan HS, Unni KES, et al: Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research 118:218-223, 2010
64. Fiedorowicz JG, Miller DD, Bishop JR, et al: Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Current Psychiatry Reviews 8:25-36, 2012
65. Keech R, Simes RJ, Barter P, et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861, 2005
66. Albert M, Glynn RJ, Fonseca F, et al: Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. American Heart Journal 162:106-114.e2; Epub June 12, 2011
67. Kizer JR, Madias C, Wilner B, et al: Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. American Journal of Cardiology 105:1289-1296, 2010
68. Sacks FM: After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. American Journal of Cardiology 102 (12A):34L-40L, 2008
69. Sever PS, Dahlöf B, Poulter NR, et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158, 2003 (Pubitemid 36398384)
70. De Hert M, Kalnicka D, van Winkel R, et al: Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 67:1889-1896, 2006 (Pubitemid 46048186)
71. Nelson LA, Graham MR, Lindsey CC, et al: Adherence to antihyperlipidemic medication and lipid control in diabetic Veterans Affairs patients with psychotic disorders. Psychosomatics 52:310-318, 2011
72. Andrus MR, East J: Use of statins in patients with chronic hepatitis C. Southern Medical Journal 103:1018-1022, 2010
73. Boccuzzi SJ, Bocanegra TS, Walker JF, et al: Long-term safety and efficacy profile of simvastatin. American journal of Cardiology 68:1127-1131, 1991
74. Webber M, Mahmud W, Lightfoot JD, et al: Rhabdomyolysis and compartment syndrome with co-administration of risperidone and simvastatin. Journal of Psychopharmacology 18:432-434, 2004 (Pubitemid 39382574)
75. Hatanaka T: Clinical pharmacokinetics of pravastatin mechanisms of pharmacokinetic events. Clinical Pharmacokinetics 39: 397-412, 2000
76. FDA Drug Safety Communication: New Restrictions, Contraindications, and Dose Limitations for Zocor (Simvastatin) to Reduce the Risk of Muscle Injury. Washington, DC, US Food and Drug Administration, 2011. Available at www.fda.gov/Drugs/DrugSafety/ucm256581.htm
77. Cilla D, Gibson D, Whitfield L, et al: Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. Journal of Clinical Pharmacology 36:604-609, 1996 (Pubitemid 26260540)
78. Williams JM, Foulds J: Successful tobacco dependence treatment in schizophrenia. American Journal of Psychiatry 164:222-227, 2007
79. Maayan L, Vakhrusheva J, Correll CU: Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35:1520-1530, 2010
80. Druss BG, Rohrbaugh RM, Levinson CM, et al: Integrated medical care for patients with serious psychiatric illness: a randomized trial. Archives of General Psychiatry 58:861-868, 2001 (Pubitemid 32979305)
81. Chen CK, Chen YC, Huang YS: Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up. Psychiatry and Clinical Neurosciences 63:17-22, 2009